Rosiglitazone Prevents CD36 Gene Expression Up-Regulation in Atherosclerosis Model
Author Information
Author(s): Y Hernandez-Trujillo, F Rodriguez-Esparragon, A Macias-Reyes, A Caballero-Hidalgo, Jose C Rodriguez-Perez
Primary Institution: Hospital Universitario de Gran Canaria Dr. Negrín
Hypothesis
Does rosiglitazone treatment preserve PPARγ activity and affect CD36 gene expression in atherosclerosis?
Conclusion
Rosiglitazone significantly reduces Nrf-2-dependent CD36 up-regulation in mice on a high-fat diet.
Supporting Evidence
- Rosiglitazone treatment maintained PPARγ activity without increasing PPARγ gene expression.
- Mice treated with rosiglitazone showed lower levels of inflammatory markers compared to those treated with losartan.
- Chromatin immunoprecipitation assays indicated that rosiglitazone prevents Nrf2-dependent CD36 up-regulation.
Takeaway
This study shows that a diabetes drug called rosiglitazone helps protect against heart problems by stopping a bad gene from getting too active in mice that eat unhealthy food.
Methodology
C57BL/6J mice were fed a high-fat high-cholesterol diet and treated with rosiglitazone or losartan for 12 weeks.
Limitations
The study was conducted in mice, which may not fully represent human responses.
Participant Demographics
C57BL/6J and C3HeJ/6J female mice
Statistical Information
P-Value
p = 0.02
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website